INTRODUCTION
The use of cell-based screens to uncover regulatory pathways has become commonplace in many fields,such as cell signaling and metabolism (Ansede and Thakker2 004; Grubisha et al. 2005; W esche et al. 2005 ). However, not all experimental systemsa re readily amenable to the development of functional screens. To be comprehensive, any screening approach must be sufficiently facile to readily analyze al arge numbero fm utants, compounds, or conditions. In addition, since any preliminary' 'hits'' are likely to be suboptimal, screens are ideally designed to allow identification and quantificationo fp artial phenotypes.
Alternative pre-mRNA splicing is currently vieweda s one of the primary mechanisms for controlling protein expression within mammalian cells, with up to 75% of human genes thought to undergo some formofalternative splicing (Black 2003; Johnson et al. 2003) . Althoughb iochemical studies have led to am echanistic understanding of the regulation of ahandful of alternative splicing events, the identificationo fs plicing regulatory proteins has been hampered by the lack of genetic screeninga pproaches. In particular, biochemical studies are not oftenwell suited for dissecting signaling pathways that may function upstream of RNA binding proteins to altert heir activity in response to growth conditions or extracellular stimuli.
As ignificantl imitationt ot he use of cell-based screens in the studyofs plicing regulation is that most instances of alternative splicing in mammals involve changes in isoform expression of <1 0-fold (Black 2003) . Several groups, including our own,h ave mades ome use of reporters that express GFP, luciferase, or ad rug resistance marker in a manner that is linearw ith regards to changes in splicing (Roberts et al. 1996; Weg-Remers et al. 2001; Sheives and Lynch 2002) . However, such assays that report directly on isoform expression do not have asufficiently large dynamic windowtoeasily identify partial perturbationsinregulation or to be amenable to high-throughput approaches.
Here we report the design and application of ad ualreporter systemt hat makes useo ft he phenomena of transcriptional synergytoamplify the response to achange in splicing. In this system the transcriptional activator Gal4-VP16 is expressed in as plicing-dependent manner and then drivest ranscriptiono fG reen Fluorescent Protein (GFP).S ince we have used proteins and promoters that havep reviously been reported to have synergistic behavior (Careyeta l. 1990) . we see ap roportional,b ut significantly enhanced, change in GFP expression relative to the fold change in splicing. Using thiss ystem we have had initial success in identifying small molecules that range in their ability to repress splicing of CD45 exon 4.
RESULTS AND DISCUSSION
To studyalternative splicing with theuse of high-throughput methods, we wanted to amplify the signal-to-background ratio of isoform detection without alteringt he physiologic relevance of the regulation. Therefore we sought systems that could be linked to an alternative splicing event to achievea no utput that is synergistic with respect to the change in splicing. The phenomenon of synergy within transcriptional regulation has been well documented. In particular, in 1990C arey et al. demonstrated that the yeast transcriptional activator Gal4,and derivatives thereof, functionedinasynergistic manner fromapromoter containing multiple activator bindings ites, such that at wo-t ot hreefold change in activator concentration yielded a10-30-fold change in transcription (Carey et al. 1990 ). Oneofthe Gal4 derivatives that was shown to have synergistic behavior was ac himericf usion of the Gal4 DNA-binding domain (Gal4 1-147) and the VP16 transcription activation domain. Importantly, the activity of thisG al4-VP16 fusion protein is largely independent of the amino acids that link the two domains and tolerates large insertions in this region (Sadowski et al. 1988 (Sadowski et al. , 1992 . Therefore, we soughtt od etermine if we could generate as plicing-dependent version of Gal4-VP16 that would reflect isoform expressiont hrough as ynergistici ncrease in the transcription of a reporterg ene.
In previous work we have extensively characterized the sequences required for the signal-responsivea lternative splicing of the human CD45 gene (Rothrock et al. 2003) . The CD45 genec ontains three variable exons that are inducibly skipped upon antigen stimulation of Tc ells or phorbol ester treatment of the T-cell-derived cell line JSL1 (Lynch and Weiss2 000) . Exon 4i st he most robustly regulated of the CD45 variable exons and contains both an exonic splicing enhancer (ESE) and as ilencer (ESS), the latero fw hich is necessary and sufficient for stimulation-inducedexon skipping (Rothrock et al. 2003) . Ac onstruct that contains allo f CD45 exon 4, flankedb ye xons derived from the human b -globin gene, has been shown previously to mimic all the hallmarks of exon 4r egulation observed within the endogenous gene (SC4) (Rothrock et al. 2003 ).
Since we are primarily interested in developing ac ellbased screen foruse in understanding the signal-dependent regulation of CD45 exon 4, we used this SC4 construct as astartingpoint for generatingthe Gal4-VP16 reporter. The codings equences for Gal4(1-147) and VP16, respectively, were fused to the flanking b -globin exons in SC4 to yield the SC-VP16s plicing minigene shown in Figure 1A (see also Materials and Methods). Inclusion of CD45 exon 4i n this constructr esults in the insertion of stop codons prior to the activation domain, leading to the production of a transcriptionallyi nactive or destabilized protein; however, when exon 4i sskipped, ap rotein is encodedthat contains the Gal4 DNA-binding domaina nd VP16 activation domain, linkedb y4 7a mino acids from the b -globin gene.
We cotransfected activation-responsive JSL1 cells with a Zeocin-resistantplasmidexpressing SC-VP16 and asecond plasmid( pG5-GFP) in which the cDNA encoding ad estabilized version of GFP (d2EGFP) is fusedd ownstream of ap romoter containing five copies of the Gal4 binding site (5xUAS G ). Following transfection, we selected individual FIGURE 1. Design of at wo-component splicing reporter that makes use of transcriptional synergy to augment detection of alternative splicing. ( A )S chematic of the SC-VP16 ( top)a nd pG5-GFP ( bottom)c onstructs that were transfected into the JSL1 cell line. For SC-VP16 the dark gray boxes represent the coding sequence for the Gal4 DNA binding domain (BD) and VP16 transcription activation domain (AD), the light gray sequences derive from the human b -globin gene and the white box is variable exon 4from the CD45 gene. For pG5-GFP the five binding sites of Gal 4(5xUASg) are shown binding to the Gal4-VP16 fusion protein and drive expression of the GFP cDNA. ( B )RT-PCR assay done under low-cycle conditions determined empirically to yield aq uantitative assessment of the change in the ratio of splicing products from the pSC-VP16 between resting ( ÿ PMA) and stimulated (+PMA) conditions. Exon 4 inclusion ( top band) to exclusion ( bottom band) ratio in resting cells is 0.9 6 0.1, though this ratio in activated cells is 0.2 6 0.05. ( C )Flow cytometry analysis of GFP expression in resting (filled) or stimulated (line) cells. Cells growing at as imilar density were washed in PBS and analyzed after gating on live cells.
Zeocin-resistantc lones. Cotransfection rates arel ow in JSL1 cells, and the pG5-GFP plasmid does not have ausable drug-resistant marker;t hus we could not assume that all of the Zeocin-resistantc lones also containedt he pG5-GFP plasmid. We therefored id as econdary selection in which cells stimulatedw ith PMA (which should increase GFP expression, as discussed below) were assayed for GFP production. Together, these two selections resulted in the isolation of 28 clones that showed expression of both the SC-VP16 and pG5-GFP plasmids.
Basedo nt he previous observations of synergistic activation of the 5xUAS G promoter by Gal4-VP16 (Carey et al. 1990 )w ea nticipatedt hat relatively small changes in the splicing of SC-VP16 pre-mRNA,a nd hence expression of the isoform encoding Gal4-VP16, might result in robust changes in GFP expressiond rivenb yt he 5xUAS G promoter.I no ur earlier studiesw ef ound that skipping of CD45 exon 4inthe context of the SC4 minigene is induced approximately threefold upon cell stimulation (Rothrock et al.2003) .Similarly, we find that in theS C-VP16 minigene there is af our-to five-fold switch towarde xon 4r epression upon stimulationw ith PMA. (Fig. 1B) . Strikingly, however, the expressiono fG FP in this samec ell linei ncreases z 30-to 50-fold upon stimulation, as measured by comparing median or peak fluorescent intensity on flow cytometry (Fig.1C) . The increasei nG FP expression occurs coincident with thet ime course of alternative splicing of SC-VP16 (datan ot shown) andisproportional to theextent of splicing regulation (see Fig. 4, below) . Thus this dual-reportert ranscriptional synergydesignsuccessfully allows forthe robust detectiono fr elativelys mall changesi na lternative splicing in living cells.
Althoughw eh ave observed similar results in several clonal lines, the data shown here areall derived from the one cell line we have chosen to use for further studies (cell line 3.14). It is worth noting, however, that only six of the 28 reporter-containingc elll ines showed apparent synergisticb ehavior similar to that of the 3.14 line (data not shown). Such al ow success rate is not surprising given that the previous studies demonstrated that synergistic activity of Gal4-VP16 is only observed over asmall range of protein expression (Careyetal. 1990) . If protein expression is too low or too high (i.e.,i nsufficient or saturating), changes in activatorconcentration have little to no effect on transcriptione fficiency. Thus,a lthought he useo ft ranscriptional synergyt of acilitatet he detectiono f alternativesplicingisofgreat value, notall dual-reportercell linesw ille xhibit synergisticb ehavior, anda no ptimal reporter cell line must be isolated empirically.
To further characterize this reporters ystem and demonstrate its utility in large-scale screening for regulators of alternative splicing, we used the 3.14 cell line in ap ilot screeno f3 00 small molecules to lookf or hits that induce skipping of CD45 exon 4. The rationale for choosing such as creenw as that numerous small molecules, sucha sP MA itself, are known to activatesignaling pathways within cells. The library we chose to screen were molecules selectedf or their druglike character and diverse functionalities (Wipf et al. 2003 (Wipf et al. ,2005 . In addition, the limited size of this library allowedf or ad etailed analysis of all compoundsb yf low cytometry.
The 3.14 cells were cultured with each of the small moleculesi ndividually, under conditions similar to those used for PMA stimulations (see Materials and Methods) and then GFP expressioni nl ive cells was measured by flow cytometry.F or the initial screens, compounds were used at af inalc oncentration of 25 m M, but subsequenta nalysis wasd one using ac oncentration of 10 m M. Most of the compounds testedh ad no effect on GFP expression in the 3.14 cells at either concentration, as shown for compound STW-2134 (Fig. 2E) . However, two hits, CRS 3-248 and XJB 1-255, induced markedup-regulation of GFP as compared to the DMSOv ehicle control ( Fig. 2A,B) . Due to convergence in the synthetic strategies used for the preparation of these small molecules, both compounds were represented multiple times in the library.I mportantly,a ll independent batches of CRS 3-248 and XJB 1-255 were indistinguishable in their ability to induceG FP expression (data not shown). In contrast,r elatively minor changes in the substitution patterns of the side chains of CRS 3-248 or XJB 1-255 either significantly decreased (Fig. 2C,D) or completely abolished (Fig.2 E) GFP induction.
To confirm that the inductionofGFP expressionbyCRS 3-248 and XJB 1-255 observed in Figure 2i si ndeed indicative of ac hange in isoform expressiono ft he SC-VP16 minigene, we directly analyzed the splicing of the SC-VP16 minigenei nc ells treated with these compounds. As shown in Figure 3 , treatment with either CRS 3-248 or XJB 1-255 induces the skipping of exon 4a pproximately one-half to one-third as much as treatment with PMA. Furthermore, as suggested by the GFP expression, compoundsSTW-2167 or STW-2110 haveonly avery marginal effect on SC-VP16 splicing. Thus,a lthough the indirect nature of our dual-reporter design theoretically raises the possibility of more false positives, for all of the compounds in which we comparedS C-VP16 RNA splicing and GFP protein expression we observed adirect correlation between the two (Fig. 4) . Indeed, when the median GFP intensity is plotteda gainst the ratio of isoform expressiono ft he SC-VP16 minigene for the compounds tested (white and gray squares), the data can be fitted to al ogarithmic curve that also intersects thedatafor DMSOand PMA(blacksquares). The fact that all the data fall closely on the fitted line confirms ac onstant proportional relationship between splicing and GFP expression. Moreover, the shapeo ft his curve is consistent with that expected fromasynergisticr elationship between isoform expression and GFP production.
One possible explanationfor howCRS 3-248 or XJB 1-255 induces kipping of CD45 exon 4, is that these compounds could be directly mimicking the activity of PMA.T oi nvestigate this possibility, we assayed the ability of CRS 3-248 and XJB 1-255 to induce other hallmarks of PMA stimulation. PMA is known to directly stimulate protein kinaseC,leading to activation of the small GTPase Ras and subsequent phosphorylation of the kinase Erk. The PMAinduced phosphorylation of Erk can be readily observed by virtue of am obility shift on an SDS-PAGE gel( Fig.5 A) ; however, parallel analysis of Erk from cells treated with either CRS 3-248orXJB 1-255 revealed no evidence of Erk phosphorylation beyond that observed in the control (DMSO) cells. In Tc ells, the PMA-induceda ctivation of Ras further leads to inducede xpression of the cell surface marker CD69, as shown by flow cytometry (Fig.5B) . Again, cells treated with either CRS 3-248 or XJB 1-255 showed no indication of inducedexpression of CD69.Weconclude that CRS 3-248 and XJB 1-255 function to induce skipping of CD45 exon 4b yamechanism that is either separate from,ordownstreamof, PMAactivationofRas.Thus, these molecules, or derivativest hereof,m ay provet ob eu seful toolst oi dentifyu nknown stepsi nt he signalingp athways that leadt oa ctivation-induced regulation of CD45 splicing.
Conclusions
Cell-based assays haveh ad limitedu tility in the splicing field because of the typically small changes in isoform expression and the difficulty in achieving asufficiently large dynamicwindowtoidentifypartial perturbationsinsplicing regulation.H erew eu tilize transcriptionals ynergy to augment the detection of regulated changes in isoform expression from as plicing minigene. This assay is based on GFP expression, which has the further advantage of permitting rapida nalysis in living cells. Although not all clones that contained the dual-reporter system demonstrated as ynergisticr esponse( as discussed above), the responseo ft hose that didhas been highly stable over multiplecell passagings. Moreover, within agiven clone there is areproducible and predictable relationship between GFP and splicing isoform expression, suchthat even small changes in GFP expression arer eflectiveo fd eviations in the normal splicing pattern. Thus,t hiss ystema llowst he accurate detectiono fs mall changesi ns plicingw iths ufficients ignal-to-noise discrimination to possibly allow true high-throughput screening.
MATERIALS AND METHODS
Plasmids pAct-SC-VP16, which expresses the Gal4-VP16 fusion protein in as plicing-dependent manner, was generated from the construct SC4 described previously (Rothrock et al. 2003) . Using PCR to add restriction sites, the coding sequence for the Gal4 DNAbinding domain (1-147) was fused upstream of 23 amino acids and the splice site of b -globin exon 1i nc onstruct SC4, while the coding sequence for the VP16 activation domain was inserted downstream of the splice site and the first 24 amino acids from b -globin exon 2. To make the GFP expression construct pG5-GFP, the cDNA for the destabilized version of GFP (d2EGFP; Clontech) was cloned downstream of five copies of the Gal4 binding site (derived from pG5-E4TLux, ag ift of Michael Carey, University of California-Los Angeles) within ap cDNA3-derived backbone. pAct-SC1-VP16 contains aZ eocin resistance cassette, while pG5-GFP contains aN eomycin resistance cassette.
Cell culture
Transfection of cells and selection of stable clones was done as described previously (Lynch and Weiss 2000) . Treatment of cells with PMA or other small molecules were done by plating cells at ad ensity of 0.3 3 10 6 per mL and adding directly to the culture media either 20 ng per mL PMA, 10 m Msmall molecule, or 1:1000 dilution of DMSO as avehicle control. Cells were incubated under these conditions for 72 h( unless specified otherwise) before harvesting cells for analysis by flow cytometry or RT-PCR. Flow cytometry analysis was done on aF ACSCalibur (BD Biosciences) as described previously (Sheives and Lynch 2002) , using either endogenous GFP fluorescence or staining with PE-conjugated anti-CD69 antibody (BD Biosciences).
RT-PCR analysis
Total RNA was harvested from cells using RNABee (Teltest) and analyzed by low-cycle RT-PCR as described previously (Rothrock et al. 2003) . Primers for RT-PCR analysis were specific to the Gal4-globin exon 1( 5 9 ÿ CGCGGATCCGCAGCCGTTACTGCCC TGTGGGGCAAGG) or globin exon 2-VP16 (59 ÿ GCTCTAGA GGCTGCGGAACCCGGACCC) junctions of the minigene, so they did not cross-react with any endogenous sequences.
Western blot analysis
Western blot analysis was done as described previously (Sheives and Lynch 2002 ) using anti-Erk antibody kindly provided by Dr. Melanie Cobb (UTSW).
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